Rheumatoid arthritis, in short RA, is one of several chronic diseases affecting the joints, characterized by the inflammation of cartilage, bone and joint lining. The inflammation will eventually result in damage to the involved joint. Inflammation can even affect skin, eyes and internal organs.
RA is an autoimmune disease in which the immune system attacks healthy joint tissue. It is the most common inflammatory rheumatic disease. The cause of RA is not known but there seems to be an inherited tendency. A general theory among experts is that the disease develops due to disturbances in the immune system. What causes the immune system to react and attack body tissue is not yet certain.
RA occurs in approximately one percent of the population and women are three times more prone than men. Although the disease often begins in middle age and occurs with increased frequency in older people, children and young adults also develop it.
Early in the disease, people may notice general fatigue, soreness, stiffness and aching before symptoms appear in the joints.
Pain and swelling may occur in the same joints on both sides of the body and will usually start in the hands, fingers or wrists. The inflammation causes swelling and pain in joints. The pain and stiffness is most pronounced in the morning and diminishes during the day. Symptoms may recede in periods, but will return. Most joints in the body can be affected but it is not possible to predict which or when.
Surgery is available if the joints become damaged and mobility is reduced. The joint is then either replaced or fixated. The pain is thus reduced and the patient is again able to perform daily chores.
Expected treatment outcome
A positive treatment effect with Salovum® can normally be seen within a few hours.
After termination of the AF products, a reduced effect can be noticed after a few weeks. If treatment is resumed, AF levels will rise within a matter of days, indicating a biological memory for AF production.
Salovum® is the recommended AF treatment for patients who have difficulties eating large amounts of SPC-Flakes®. Studies also indicate that patients not responding to treatment with SPC-Flakes® may respond to Salovum®.
For seriously ill patients or in patients with suspected low AF-levels, treatment with Salovum® quickly raises AF-levels directly in the intestine. Most often the patients initially treated with Salovum® can thereafter be transferred to the AF-inducing SPC-Flakes® in order to stimulate the body’s own production of AF.
The normal dosage of Salovum® is 4 g three times daily. The powder is blended with a cold liquid, e.g juice or water, preferably using a whisk or a blender.
To stimulate the endogenous production of AF it is favourable to introduce AF inducing cereals, SPC-Flakes®, during treatment with, or as a follow-up treatment towards the end to, Salovum®.
Side effects, interactions and precautions
AF products have been eaten by tens of thousands of individuals and no side effects of medical nature have been reported. A few patients have experienced occasional constipation, but this discomfort can be reduced by a step-by-step introduction of the treatment.
There are no reported interactions with concomitant medications. This is of importance as the patients should continue with their regular medical treatment. Salovum® should not replace or change the patients’ current medication. Persons with allergy to eggs should not be treated with Salovum®.
Where to buy, Prescriptions
Salovum® can be bought prescription free in pharmacies. As of December 31, 2010, Läkemedelsverket (The Medical Products Agency) has decided to include Salovum® and SPC-Flakes® in the new revised list for food for particular nutritional use for children under 16 years of age and the cost will thus be included within the national benefit scheme for prescription drugs.
For patients 16 years of age or older, dieticians and most doctors can prescribe Salovum® as “sär-när”, foods for particular nutritional uses certified by the National Food Administration (Livsmedelsverket). The cost of the products varies between the different counties (landsting).
Sweden: The pharmacies may not have Salovum® in stock, but they can in that case order it within 1-2 days. The reference number (varunummer) for Salovum is 21 06 81 .
Norway: In Norway, both SPC-Flakes® and Salovum® can be prescribed by physicians (blå resept), see links, [http://www.helfo.no/helsepersonell/lege/legemidler/Sider/neringsmidler.aspx] [http://www.legemiddelverket.no/upload/Bl%C3%A5reseptforskriften.pdf]. and link to the Product Catalogue (p 8, Spesialløsninger) [http://www.helfo.no/SiteCollectionDocuments/Vedlegg%20helsepersonell/Grossister%20og%20leverand%C3%B8rer/Produkt-og%20prislister%20fra%2001.07.10/N%C3%A6ringsmidler%2001.07.2010.pdf] Salovum® can also be ordered from Poa Pharma Scandinavia AB, see link
Denmark: Salovum® can be ordered from Poa Pharma Scandinavia AB, see link
Finland: Salovum® can be ordered from Poa Pharma Scandinavia AB, see link